Activation of the growth-differentiation factor 11 gene by the histone deacetylase (HDAC) inhibitor trichostatin A and repression by HDAC3

Molecular and Cellular Biology

Volumn 24, Issue 12, 2004, Pages 5106-5118

  Zhang, Xiaohong ^a   Wharton, Walker ^a   Yuan, Zhigang ^a   Tsai, Shih Chang ^a   Olashaw, Nancy ^a   Seto, Edward ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT BINDING FACTOR; GROWTH DIFFERENTIATION FACTOR 11; GROWTH DIFFERENTIATION FACTOR 5; HISTONE DEACETYLASE INHIBITOR; LYSINE; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ACETYLATION; ANIMAL CELL; ARTICLE; CATALYSIS; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME INHIBITION; GDF11 GENE; GENE; GENE ACTIVATION; GENE IDENTIFICATION; GENE REPRESSION; HDAC3 GENE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; TUMOR GROWTH;

ACETYLATION; ANIMALS; BALB 3T3 CELLS; BASE SEQUENCE; BONE MORPHOGENETIC PROTEINS; CELL LINE; DNA, COMPLEMENTARY; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; GENE SILENCING; HELA CELLS; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; LYSINE; MICE; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; RNA, SMALL INTERFERING;

ANIMALIA;

EID: 2942594784     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.24.12.5106-5118.2004     Document Type: Article

References (71)

1. Agalioti, T., G. Chen, and D. Thanos. 2002. Deciphering the transcriptional histone acetylation code for a human gene. Cell 111:381-392.
2. Armand, A. S., B. Della Gaspera, T. Launay, F. Charbonnier, C. L. Gallien, and C. Chanoine. 2003. Expression and neural control of follistatin versus myostatin genes during regeneration of mouse soleus. Dev. Dyn. 227:256-265.
3. Boyd, K. E., and P. J. Farnham. 1999. Coexamination of site-specific transcription factor binding and promoter activity in living cells. Mol. Cell. Biol. 19:8393-8399.
4. Butler, L. M., X. Zhou, W. S. Xu, H. I. Scher, R. A. Rifkind, P. A. Marks, and V. M. Richon. 2002. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc. Natl. Acad. Sci. USA 99:11700-11705.
5. Carmen, A. A., S. E. Rundlett, and M. Grunstein. 1996. HDA1 and HDA3 are components of a yeast histone deacetylase (HDA) complex. J. Biol. Chem. 271:15837-15844.
6. Darkin-Rattray, S. J., A. M. Gurnett, R. W. Myers, P. M. Dulski, T. M. Crumley, J. J. Allocco, C. Cannova, P. T. Meinke, S. L. Colletti, M. A. Bednarek, S. B. Singh, M. A. Goetz, A. W. Dombrowski, J. D. Polishook, and D. M. Schmatz. 1996. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. USA 93:13143-13147.
7. Della Ragione, F., V. Criniti, V. Della Pietra, A. Borriello, A. Oliva, S. Indaco, T. Yamamoto, and V. Zappia. 2001. Genes modulated by histone acetylation as new effectors of butyrate activity. FEBS Lett. 499:199-204.
8. Eickhoff, B., L. Germeroth, C. Stahl, G. Kohler, S. Ruller, M. Schlaak, and J. van der Bosch. 2000. Trichostatin A-mediated regulation of gene expression and protein kinase activities: reprogramming tumor cells for ribotoxic stress-induced apoptosis. Biol. Chem. 381:1127-1132.
9. Esquela, A. F., and S. J. Lee. 2003. Regulation of metanephric kidney development by growth/differentiation factor 11. Dev. Biol. 257:356-370.
10. Fischle, W., F. Dequiedt, M. Fillion, M. J. Hendzel, W. Voelter, and E. Verdin. 2001. Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J. Biol. Chem. 276:35826-35835.
11. Fischle, W., Y. Wang, and C. D. Allis. 2003. Histone and chromatin crosstalk. Curr. Opin. Cell Biol. 15:172-183.
12. Gamer, L. W., K. A. Cox, C. Small, and V. Rosen. 2001. Gdf11 is a negative regulator of chondrogenesis and myogenesis in the developing chick limb. Dev. Biol. 229:407-420.
13. Gamer, L. W., N. M. Wolfman, A. J. Celeste, G. Hattersley, R. Hewick, and V. Rosen. 1999. A novel BMP expressed in developing mouse limb, spinal cord, and tail bud is a potent mesoderm inducer in Xenopus embryos. Dev. Biol. 208:222-232.
14. Ghoshal, K., J. Datta, S. Majumder, S. Bai, X. Dong, M. Parthun, and J. T. Samson. 2002. Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure. Mol. Cell. Biol. 22:8302-8319.
15. Glaser, K. B., M. J. Staver, J. F. Waring, J. Stender, R. G. Ulrich, and S. K. Davidsen. 2003. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2:151-163.
16. Grozinger, C. M., C. A. Hassig, and S. L. Schreiber. 1999. Three proteins define a class of human histone deacetylases related to yeast Hdalp. Proc. Natl. Acad. Sci. USA 96:4868-4873.
17. Guardiola, A. R., and T. P. Yao. 2002. Molecular cloning and characterization of a novel histone deacetylase HDAC10. J. Biol. Chem. 277:3350-3356.
18. Guenther, M. G., W. S. Lane, W. Fischle, E. Verdin, M. A. Lazar, and R. Shiekhattar. 2000. A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes Dev. 14:1048-1057.
19. WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl. Acad. Sci. USA 101:1241-1246.
20. He, L. Z., T. Tolentino, P. Grayson, S. Zhong, R. P. Warrell, Jr., R. A. Rifkind, P. A. Marks, V. M. Richon, and P. P. Pandolfi. 2001. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Investig. 108:1321-1330.
21. Hirose, T., Y. Sowa, S. Takahashi, S. Saito, C. Yasuda, N. Shindo, K. Furuichi, and T. Sakai. 2003. p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y. Oncogene 22:7762-7773.
22. Hou, M., X. Wang, N. Popov, A. Zhang, X. Zhao, R. Zhou, A. Zetterberg, M. Bjorkholm, M. Henriksson, A. Gruber, and D. Xu. 2002. The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells. Exp. Cell Res. 274:25-34.
23. Ishizuka, T., and M. A. Lazar. 2003. The N-CoR/histone deacetylase 3 complex is required for repression by thyroid hormone receptor. Mol. Cell. Biol. 23:5122-5131.
24. Jin, S., and K. W. Scotto. 1998. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol. Cell. Biol. 18:4377-4384.
25. Jin, S., B. Gorfajn, G. Faircloth, and K. W. Scotto. 2000. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc. Natl. Acad. Sci. USA 97:6775-6779.
26. Johnstone, R. W. 2002. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1:287-299.
27. Johnstone, R. W., and J. D. Licht. 2003. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell. 4:13-18.
28. Kao, H. Y., M. Downes, P. Ordentlich, and R. M. Evans. 2000. Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Genes Dev. 14:55-66.
29. Kim, H. S., J. S. Park, S. J. Hong, M. S. Woo, S. Y. Kim, and K. S. Kim. 2003. Regulation of the tyrosine hydroxylase gene promoter by histone deacetylase inhibitors. Biochem. Biophys. Res. Commun. 312:950-957.
30. Koeller, K. M., S. J. Haggarty, B. D. Perkins, I. Leykin, J. C. Wong, M. C. Kao, and S. L. Schreiber. 2003. Chemical genetic modifier screens. Small molecule trichostatin suppressors as probes of intracellular histone and tubulin acetylation. Chem. Biol. 10:397-410.
31. Laherty, C. D., W. M. Yang, J. M. Sun, J. R. Davie, E. Seto, and R. N. Eisenman. 1997. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell 89:349-356.
32. Lee, H., S. Lee, M. Baek, H.-Y. Kim, and D.-I. Jeoung. 2002. Expression profile analysis of trichostatin A in human gastric cancer cells. Biotechnol. Lett. 24:377-381.
33. Li, J., J. Wang, Z. Nawaz, J. M. Liu, J. Qin, and J. Wong. 2000. Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J. 19:4342-4350.
34. Lin, S. Y., J. R. Morrison, D. J. Phillips, and D. M. de Kretser. 2003. Regulation of ovarian function by the TGF-beta superfamily and follistatin. Reproduction 126:133-148.
35. Luo, W., and D. G. Skalnik. 1996. CCAAT displacement protein competes with multiple transcriptional activators for binding to four sites in the proximal gp91phox promoter. J. Biol. Chem. 271:18203-18210.
36. Marks, P. A., T. Miller, and V. M. Richon. 2003. Histone deacetylases. Curr. Opin. Pharmacol. 3:344-351,
37. Marks, P. A., V. M. Richon, R. Breslow, and R. A. Rifkind. 2001. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13:477-483.
38. Marks, P. A., V. M. Richon, and R. A. Rifkind. 2000. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92:1210-1216.
39. Marks, P. A., R. A. Rifkind, V. M. Richon, and R. Breslow. 2001. Inhibitors of histone deacetylase are potentially effective anticancer agents. Clin. Cancer Res. 7:759-760.
40. Marks, P. A., R. A. Rifkind, V. M. Richon, R. Breslow, T. Miller, and W. K. Kelly. 2001. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1:194-202.
41. Matzuk, M. M., N. Lu, H. Vogel, K. Sellheyer, D. R. Roop, and A. Bradley. 1995. Multiple defects and perinatal death in mice deficient in follistatin. Nature 374:360-363.
42. McPherron, A. C., A. M. Lawler, and S. J. Lee. 1999. Regulation of anterior/posterior patterning of the axial skeleton by growth/differentiation factor 11. Nat. Genet. 22:260-264.
43. McPherron, A. C., A. M. Lawler, and S. J. Lee. 1997. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387:83-90.
44. Neufeld, E. J., D. G. Skalnik, P. M. Lievens, and S. H. Orkin. 1992. Human CCAAT displacement protein is homologous to the Drosophila homeoprotein, cut. Nat. Genet. 1:50-55.
45. Oh, S. P., C. Y. Yeo, Y. Lee, H. Schrewe, M. Whitman, and E. Li. 2002. Activin type IIA and IIB receptors mediate Gdf11 signaling in axial vertebral patterning. Genes Dev. 16:2749-2754.
46. Park, S. H., S. R. Lee, B. C. Kim, E. A. Cho, S. P. Patel, H. B. Kang, E. A. Sausville, O. Nakanishi, J. B. Trepel, B. I. Lee, and S. J. Kim. 2002. Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells. J. Biol. Chem. 277:5168-5174.
47. Richon, V. M., T. W. Sandhoff, R. A. Rifkind, and P. A. Marks, 2000. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA 97:10014-10019.
48. Sambucetti, L. C., D. D. Fischer, S. Zabludoff, P. O. Kwon, H. Chamberlin, N. Trogani, H. Xu, and D. Cohen. 1999. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem. 274:34940-34947.
49. Schuettengruber, B., E. Simboeck, H. Khier, and C. Seiser. 2003. Autoregulation of mouse histone deacetylase 1 expression. Mol. Cell. Biol. 23:6993-7004.
50. Shang, Y., X. Hu, J. DiRenzo, M. A. Lazar, and M. Brown. 2000. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103:843-852.
51. Sowa, Y., T. Orita, S. Minamikawa, K. Nakano, T. Mizuno, H. Nomura, and T. Sakai. 1997. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem. Biophys. Res. Commun. 241:142-150.
52. Steffan, J. S., L. Bodai, J. Pallos, M. Poelman, A. McCampbell, B. L. Apostol, A. Kazantsev, E. Schmidt, Y. Z. Zhu, M. Greenwald, R. Kurokawa, D. E. Housman, G. R. Jackson, J. L. Marsh, and L. M. Thompson. 2001. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413:739-743.
53. Sui, G., C. Soohoo, B. Affar el, F. Gay, Y. Shi, W. C. Forrester, and Y. Shi. 2002. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. USA 99:5515-5520.
54. Taunton, J., C. A. Hassig, and S. L. Schreiber. 1996. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272:408-411.
55. Tsuji, N., M. Kobayashi, K. Nagashima, Y. Wakisaka, and K. Koizumi. 1976. A new antifungal antibiotic, trichostatin. J. Antibiot. 29:1-6.
56. Urnov, F. D., J. Yee, L. Sachs, T. N. Collingwood, A. Bauer, H. Beug, Y. B. Shi, and A. P. Wolffe. 2000. Targeting of N-CoR and histone deacetylase 3 by the oncoprotein v-erbA yields a chromatin infrastructure-dependent transcriptional repression pathway. EMBO J. 19:4074-4090.
57. Valarche, I., J. P. Tissier-Seta, M. R. Hirsch, S. Martinez, C. Goridis, and J. F. Brunet. 1993. The mouse homeodomain protein Phox2 regulates Ncam promoter activity in concert with Cux/CDP and is a putative determinant of neurotransmitter phenotype. Development 119:881-896.
58. Van Lint, C., S. Emiliani, and E. Verdin. 1996. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 5:245-253.
59. 1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals. Cell Growth Differ. 9:465-474.
60. Wang, A., S. K. Kurdistani, and M. Grunstein. 2002. Requirement of Hos2 histone deacetylase for gene activity in yeast. Science 298:1412-1414.
61. Wang, S., Y. Yan-Neale, D. Fischer, M. Zeremski, R. Cai, J. Zhu, F. Asselbergs, G. Hampton, and D. Cohen. 2003. Histone deacetylase 1 represses the small GTPase RhoB expression in human nonsmall lung carcinoma cell line. Oncogene 22:6204-6213.
62. Wen, Y. D., W. D. Cress, A. L. Roy, and E. Seto. 2003. Histone deacetylase 3 binds to and regulates the multifunctional transcription factor TFII-I. J. Biol. Chem. 278:1841-1847.
63. Wen, Y. D., V. Perissi, L. M. Staszewski, W. M. Yang, A. Krones, C. K. Glass, M. G. Rosenfeld, and E. Seto. 2000. The histone deacetylase-3 complex contains nuclear receptor corepressors. Proc. Natl. Acad. Sci. USA 97:7202-7207.
64. Wharton, W., J. Savell, W. D. Cress, E. Seto, and W. J. Pledger. 2000. Inhibition of mitogenesis in Balb/c-3T3 cells by trichostatin A. Multiple alterations in the induction and activation of cyclin-cyclin-dependent kinase complexes. J. Biol. Chem. 275:33981-33987.
65. Wu, H. H., S. Ivkovic, R. C. Murray, S. Jaramillo, K. M. Lyons, J. E. Johnson, and A. L. Calof. 2003. Autoregulation of neurogenesis by GDF11. Neuron 37:197-207.
66. Xiao, H., T. Hasegawa, and K. Isobe. 1999. Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells. J. Cell. Biochem. 73:291-302.
67. 1 and G2 phases by trichostatin A. Exp. Cell Res. 177:122-131.
68. Yoshida, M., R. Furumai, M. Nishiyama, Y. Komatsu, N. Nishino, and S. Horinouchi. 2001. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother. Pharmacol. 48:S20-S26.
69. Yoshida, M., S. Horinouchi, and T. Beppu. 1995. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays 17:423-430.
70. Yoshida, M., M. Kijima, M. Akita, and T. Beppu. 1990. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265:17174-17179.
71. Zhou, X., P. A. Marks, R. A. Rifkind, and V. M. Richon. 2001. Cloning and characterization of a histone deacetylase, HDAC9. Proc. Natl. Acad. Sci. USA 98:10572-10577.